Clinical Trial Update: Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating subcutaneous immunoglobulin with modified dosing regimens in patients with primary immunodeficiency disorders has completed; results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Diseases

Drugs mentioned

• Octapharma subcutaneous immunoglobulin (immunoglobulin)

Snippet

Sponsor: Octapharma | Conditions: Primary Immune Deficiency Disorder | Phase 3 | Status: COMPLETED | Results posted: 2023-11-07